In this context, it is sobering to rethink the adjuvant administration of recombinant CSF2 to ameliorate therapy-induced neutropenia in CSF2-releasing cancers 49, such as myxofibrosarcomas with overexpressed and activated PAK1, which is at risk of detrimental cancer-promoting effect. The gene discussed is CSF2; the disease is Decreased total neutrophil count.